Teresa DeLuca, M.D., MBA has served as a director of Surgery Partners since September 2016. Dr. DeLuca served as a Managing Director at Columbia University's NY Life Science Venture Fund from January 2018 until January 2020 and continues to serve as a Faculty Advisor at the University s School of Entrepreneurship and Faculty Member of Columbia University School of Professional Studies. She previously served as Assistant Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City from 2014 to 2017 and as the Chief Medical Officer of Magellan Pharmacy Solutions at Magellan Health from 2012 to 2014. Prior to that, she served as SVP of Pharmacy Health Solutions at Humana, National Medical Director & VP of Clinical Sales Solutions at Walgreen Co., and as VP of Personalized Medicine, VP of Medical Policy & Clinical Quality and Chief Medical Officer United Health Group at Medco. Prior to taking on these executive leadership roles, Dr. DeLuca was a Senior Director of Global Product Development Services at PRA International and a Senior Medical Scientist at GlaxoSmithKline. Dr. DeLuca serves as a director of Life Stance, a public behavioral healthcare company, since 2024. Previously served as a director of Rejuveron, a private Swiss drug discovery company from March 2022 to July 2025. She also previously served as a director of 180 Life Science, a public biotechnology company, from May 2021 to December 2023. She also served as a director of North Bud Farms, Inc., a private to public pharmaceutical commercialization company, from May 2018 to February 2020. Dr. DeLuca completed her residency (M.D.) at Jefferson Medical College of Thomas Jefferson University and earned her M.B.A. from Drexel University. As a strong advocate for good board governance, Dr. DeLuca earned the Carnegie Mellon Cybersecurity Certificate in 2016 and passed the Digital Directors Network Cyber Risk Masterclass examination for Public Companies in 2022. Dr. DeLuca has continued to maintain good standing with the National Association of Corporate Directors (NACD) as a Board Leadership Fellow (Master Level) since 2016. Dr. DeLuca has also passed the NACD s Directorship Certified examination (NACD.DC) in 2020. In 2023, she became a NACD Subject Matter Expert in examination development and a Board Advisory Faculty Member, and in 2024 began serving as a NACD Certification Commissioner. Dr. DeLuca was named in 2025 as NACD Directorship Certification Ambassador Inaugural Class. She has also earned the American College of Corporate Directors (ACCD) Master Professional Director Public Company credential in 2021. Dr. DeLuca was named a Director to Watch in the 2020 Directors & Board Annual Report and a Featured Director of the Month in 2022 by the Chief Executive Group. In 2022, Dr. DeLuca became Co-Chair and Leadership Council Member for the international organization, Women Corporate Directors (WCD). In 2024 she was named to Who s Who in America and joined Madam Chair in 2025. Our Board believes that Dr. DeLuca is qualified to serve as a director based on, among other things, her healthcare knowledge, experience and skills gained from being a physician with active multiple medical licenses, as well as previously serving as a Fortune 50 Chief Medical Officer and P&L business line owner.